Indian Researchers have found a new Stem cell protein that can help find a cure for blood cancer
Stem Cells are getting so much reputation of knowing as a wonder treatment. Now, Indian Researchers have identified a stem cell protein that may play an important role in finding a cure for blood cancer.
Researchers performed a study on mouse suggesting that a stem cell protein called Asrij, can act as a novel regulator of wild type tumor suppressor p53 stability in the hematopoietic stem cells (HSCs).
According to researchers, including Maneesha S. Inamdar from the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru(India) said that It could help design targeted therapies for the myeloproliferative disease which is a group of slow-growing blood cancers.
The Researchers were positive saying that they had provided a new mouse model resembling the myeloproliferative disease and it helped them identifying a post-translational regulator of wild type p53. This is essential for maintaining HSC quiescence that could be a potential target for pharmacological intervention.
The Entire Study was published in the journal Blood and it explains that inactivation of the tumor suppressor p53 is essential for unrestrained growth of cancers. But unfortunately, only 11 percent of hematological malignancies have mutant p53. The study further suggests that Mechanisms that cause wild type p53 dysfunction and promote leukemia(Blood Cancer) are inadequately deciphered.
The team explained that the stem cell protein Asrij is misexpressed in several human hematological malignancies and it has been implicated in the p53 pathway and DNA damage response.
The study had some hurdles and in order to perform this study, the team generated the first Asrij null (knockout, KO) in mice. The researchers were pumped seeing that the mice showed that they are viable and fertile with no gross abnormalities. However, This success was short-lived after six months the mice exhibited increased peripheral blood cell counts, splenomegaly and expansion of bone marrow HSCs with the higher myeloid output.